BIG BANG study: A multicenter phase II study of the MEK inhibitor binimetinib + BRAF inhibitor encorafenib + anti-EGFR antibody cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer (EPOC 1703)

Authors:

Abstract
Background: While BRAF mutations occur in 10-15% of metastatic colorectal cancer (mCRC), BRAF Non-V600E mutations was recently reported with ranging 2.2 - 5.2%. We have reported that BRAF Non-V600E could be a negative impact on survival outcome as well as anti-EGFR antibody treatment for pretreated mCRC patients (Shinozaki E, et al. Br J Cancer 2017). In addition, simultaneous inhibitions of MEK, BRAF and EGFR exhibited most potent anti-tumor activities in BRAF Non-V600E mutant cell lines and xenografted models (unpublished data).